產(chǎn)品名稱：VX-702, Free Base 產(chǎn)品貨號：LC V-9366 產(chǎn)品規(guī)格：1 G VX-702 is a second-generation, orally active mitogen-activated protein kinase (MAPK) p38 inhibitor. It is being tested for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. Ding, C. "Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome." Curr. Opin. Investig. Drugs 7: 1020-1025 (2006). p38 MAPK increases thromboxane levels by activating phospholipase A2, thus catalyzing the formation of arachidonic acid. VX-702 inhibited activation of p38 MAPK by thrombin, SFLLRN, AYPGKF and U46619 in platelets. Kuliopulos, A., et al. "Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation." Thromb. Haemost. 92: 1387-1393 (2004). VX-702 showed modest clinical efficacy and transient suppression of biomarkers of inflammation in patients with rheumatoid arthritis. Damjanov, N., et al. "Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies." Arthritis Rheum. 60: 1232-1241 (2009). Another CAS number previously assigned to VX-702, 479543-46-9, has been deleted by CAS and is no longer in use. Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A
滬公網(wǎng)安備 31011002002623號
